Format

Send to

Choose Destination
Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700187. Epub 2017 Sep 13.

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Author information

1
Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.

Abstract

Oncolytic viruses (OVs) are novel anticancer agents that combine direct cancer cell killing with the stimulation of antitumor immunity. In addition, OVs can be engineered to deliver biological therapeutics directly to tumors, offering unique opportunities to design multimodal anticancer strategies. Here, a case for arming OVs with bispecific T cell engagers (BiTEs) is put forward. BiTEs redirect the cytotoxicity of polyclonal T cells to target cells of choice, and have demonstrated efficacy against a number of hematological cancers. However, the success of BiTEs in the treatment of solid tumors appears more limited, at least in part due to: (i) poor delivery kinetics and penetration into tumors, and (ii) on-target off-tumor activity, leading to dose-limiting toxicities. Linking the production of BiTEs to OV replication provides an exciting means to restrict production to the tumor site, widen their therapeutic window, and synergize with direct oncolysis. This review summarizes progress thus far in the preclinical development of BiTE-armed OVs, and explores the possibility of cotargeting cancer cells and nontransformed stromal cells.

KEYWORDS:

T cell therapy; Tumor microenvironment; bispecific T cell engagers; immunotherapy; oncolytic viruses

PMID:
28902983
DOI:
10.1002/mabi.201700187
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center